| Ytd | 4.76% | |
| 1y | 21.68% |
| Open | 0.74 | Prev Close | 0.74 | Low | 0.72 | High | 0.75 | Mkt Cap | 161.86M |
| Vol | 1.24M | Avg Vol | 3.61M | EPS | -0.44 | P/E | N/A | Forward P/E | -1.28 |
| Beta | 2.35 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 0.77 | 200-d Avg | 0.98 | 1yr Est | 18.50 |
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Exper
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PK
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the an
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering
HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneo
The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenay
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with M
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Bl
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter resu
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the
Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Th
Gainers Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase ag
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
On Wednesday, 283 companies set new 52-week lows.
Friday's session saw 236 companies set new 52-week lows.
During Monday's session, 101 companies made new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
During Monday's trading, 528 companies set new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Monday, 429 stocks made new 52-week lows.